Summary

Heart Pump Device Market Size and Forecast 2026-2034
Heart Pump Device Market is expected to reach US$ 8.61 billion by 2034 from US$ 2.93 billion in 2025, with a CAGR of 12.72% from 2026 to 2034. The heart pump device market is expected to register steady growth, driven by rising cardiovascular disease prevalence, increasing heart failure cases, technological advancements in mechanical circulatory support systems, and expanding access to advanced cardiac care globally.

Heart Pump Device Industry Overview
The heart pump device market represents a critical segment of the global cardiovascular medical devices industry, focused on providing mechanical circulatory support for patients suffering from severe heart failure or end-stage cardiac conditions. Heart pump devices, including ventricular assist devices (VADs), intra-aortic balloon pumps, and total artificial hearts, are increasingly used as either a bridge to transplantation or as long-term therapy for patient’s ineligible for heart transplants. The rising global burden of cardiovascular diseases, driven by aging populations, sedentary lifestyles, obesity, and diabetes, has significantly increased demand for advanced heart failure treatment options. Healthcare systems are increasingly adopting innovative cardiac support technologies to improve survival rates and patient quality of life.
Technological innovation is playing a transformative role in the market, with manufacturers focusing on miniaturization, biocompatible materials, improved durability, and enhanced energy efficiency of heart pump devices. Continuous-flow ventricular assist devices and fully implantable systems are improving patient mobility and reducing complication risks. Integration of digital monitoring systems and remote patient management technologies is also enhancing post-operative care and device performance tracking. In addition, improvements in surgical techniques and cardiac care infrastructure are increasing the success rate of implantation procedures. Hospitals and specialized cardiac centers are expanding their capabilities to handle complex heart failure cases, further driving adoption of these devices across developed and emerging healthcare systems.
Over 6.2 million Americans suffer from heart failure, but there are still only about 3,500 donor hearts available each year. Demand exceeds supply since incidence doubles every ten years beyond age 65, making mechanical circulatory support a primary treatment. The Impella platform for children was cleared by the FDA in December 2024, demonstrating how technology is bridging age-group gaps in a burdened transplant ecosystem. Since five-year LVAD survival rates are currently at 63%, doctors are encouraged to suggest long-term care even for elderly patients who are ineligible for transplants. When combined, these clinical and demographic facts support the market for heart pump devices' long-term expansion.

Growth Drivers for the Heart Pump Device Market
Increasing Adoption of Mechanical Circulatory Assistance
One of the main factors driving the global market for heart pump devices is the increasing adoption of mechanical circulatory support (MCS). In a recent cohort, for example, 78% of children receiving mechanical circulatory assistance with a pCF pump had a favorable outcome. MCS devices like VADs are becoming vital therapeutic choices for patients due to the rising incidence of heart failure and the scarcity of donor organs for transplantation. For example, it is anticipated that over 60 million individuals globally suffer from heart failure in 2025, and the burden is expected to increase due to an aging population. As a result, patients and healthcare professionals are depending more on MCS, which has the potential to increase longevity, enhance quality of life, and act as a bridge to destination therapy or transplantation. As a result, the market prognosis for heart pump devices is improving.

Bridge to Destination Therapy and Transplant
The requirement for heart pump devices as a palliative measure prior to transplant and destination therapy is one of the main factors driving the global market for these devices. VADs are used as a temporary or long-term treatment for patients who are awaiting a heart transplant or who are ineligible for one. With estimates indicating that over 6.5 million Americans over 20 suffer heart failure, there is an increasing need for effective bridge-to-transplant and destination therapy options. Additionally, another study found that 960,000 new cases of heart failure are recorded annually, increasing the need for heart pump devices in these therapeutic settings.

Technological Developments in Heart Pumps
The global market for heart pump devices is expanding and innovating due to the advancement of heart pump technologies. Heart pump devices that are more durable, biocompatible, and effective have been developed as a result of improved device functionality, novel materials, and shrinking techniques. For example, SynCardia is constantly developing new concepts for its complete artificial heart (TAH). They have received a new patent for their next-generation TAH designs for end-stage biventricular failure patients awaiting a heart transplant. Furthermore, the integration of contemporary monitoring systems and data analytics has enabled the customization of patient management and remote monitoring, enhancing overall patient care and safety. The market for these life-saving devices is growing, according to the heart pump device market prediction, and heart pump technology is continually being studied and developed.

Challenges in the Heart Pump Device Market
High Cost of Devices and Treatment Procedures
One of the major challenges in the heart pump device market is the high cost associated with devices, surgical implantation, and post-operative care. These systems require specialized surgical expertise, intensive care, and long-term monitoring, making treatment expensive for patients and healthcare systems. Limited reimbursement coverage in some regions further restricts access to advanced cardiac assist devices. The high financial burden can delay adoption, particularly in developing economies where healthcare budgets are constrained. Manufacturers and healthcare providers are working to improve cost efficiency and expand insurance coverage to enhance accessibility.

Risk of Complications and Device-Related Infections
Heart pump devices are associated with potential risks such as blood clots, infections, bleeding, and device malfunction. These complications require careful patient monitoring and long-term medical management. Implantable devices also involve surgical risks and post-operative challenges that can impact patient outcomes. Infection at the implantation site and device-related thrombosis remain key concerns in clinical use. Continuous advancements in device design, biocompatible materials, and infection control protocols are being developed to reduce these risks and improve overall patient safety.

United States Heart Pump Device Market
The United States heart pump device market is highly advanced, driven by strong healthcare infrastructure, high cardiovascular disease prevalence, and widespread adoption of innovative medical technologies. The country has a large number of specialized cardiac centers equipped to perform complex ventricular assist device implantation procedures. Favorable reimbursement policies and strong insurance coverage support patient access to advanced heart failure treatments. Continuous research and clinical trials conducted by leading medical institutions are driving innovation in mechanical circulatory support systems. Increasing aging population and rising heart failure cases continue to sustain demand for heart pump devices across the United States healthcare system.

Germany Heart Pump Device Market
Germany represents a key European market for heart pump devices, supported by its advanced healthcare system, strong medical device industry, and high standards of cardiac care. The country has well-established hospitals and cardiac centers specializing in heart failure management and surgical interventions. Increasing prevalence of cardiovascular diseases and strong focus on medical innovation are driving adoption of advanced heart pump technologies. Germany also plays a significant role in clinical research and development of next-generation cardiac assist devices. Continued healthcare investments and emphasis on improving patient outcomes are expected to support steady market growth.

India Heart Pump Device Market
India’s heart pump device market is emerging, supported by rising cardiovascular disease burden, improving healthcare infrastructure, and increasing access to advanced cardiac treatments. Growing awareness of heart failure management and expanding private healthcare facilities are driving demand for advanced cardiac devices. However, high treatment costs remain a barrier to widespread adoption. Leading metropolitan hospitals are increasingly adopting ventricular assist devices for critical care patients. For example, around 70 specialist hospitals in India do between 90 and 100 heart transplants annually. Early start of heart diseases is being caused by dietary trends, lifestyle modifications, and increased pollutants. In urgent situations where a heart transplant is either unavailable or delayed, heart pump devices are being used. Government initiatives to improve healthcare access and growing medical tourism are also contributing to market expansion. As healthcare infrastructure continues to develop, demand for heart pump devices is expected to increase gradually in India.

United Arab Emirates Heart Pump Device Market
The UAE heart pump device market is developing steadily, supported by advanced healthcare infrastructure, high healthcare spending, and growing prevalence of cardiovascular diseases. The country has modern hospitals and specialized cardiac centers offering advanced treatment options for heart failure patients. Increasing medical tourism and access to cutting-edge medical technologies are further supporting market growth. Government investments in healthcare modernization and adoption of global medical standards are enhancing availability of advanced cardiac devices. As awareness of cardiovascular health increases and healthcare capabilities expand, the UAE is expected to see growing adoption of heart pump devices for critical care management.

Recent Developments in Heart Pump Device Market
- July 2025: At St. Vincent's Hospital in Australia, a patient with advanced heart failure had the first implant of CorWave's heart pump system, which uses undulating membrane technology. After 30 days, the patient was released without any issues, the device maintained natural heart pulsatility, and early results were encouraging.
- May 2025: In comparison to the current HeartMate 3, a multicenter U.S. clinical trial assessed the safety and effectiveness of the BrioVAD heart pump device as a novel LVAD alternative for severe heart failure. Cleveland Clinic was one of eight locations where the magnetically levitated pump technology of BrioVAD was evaluated.
- May 2025: Abbott received FDA approval for its Tendyne™ heart pump device, the first transcatheter system designed to replace the mitral valve without open-heart surgery, offering a minimally invasive solution for patients with severe mitral annular calcification who were not eligible for traditional surgical treatments.
- March 2025: Following its upgrading to Class 2a in the ACC/AHA treatment guidelines for cardiogenic shock subsequent to STEMI, Johnson & Johnson MedTech demonstrated the survival benefits of its Impella heart pump device at ACC.25. The update acknowledged Impella's capacity to enhance patient outcomes and influenced a number of talks around guideline-driven treatment.

Market Segmentations
Product
- Ventricular Assist Devices (VADs)
- Intra-aortic balloon pumps (IABPs)
- Extracorporeal Membrane Oxygenation (EMCO)
- Total Artificial Hearts (TAHs)

Type
- Implanted Heart Pump Device
- Extracorporeal Heart Pump Device

End Use
- Hospitals
- Cardiac Centers
- Research Institutes

Regional Outlook
North America
- United States
- Canada

Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Turkey

Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Malaysia
- Indonesia
- New Zealand

Latin America
- Brazil
- Mexico
- Argentina

Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates

All the Key players have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments
- SWOT Analysis
- Revenue Analysis

Company Analysis:
- Abbott Inc.
- Getinge AB.
- Teleflex Incorporated
- Fresenius SE & Co. KGaA
- LivaNova PLC
- CorWave SA
- JARVIK HEART, INC.
- ABIOMED

ページTOPに戻る

Table of Contents

1. Introduction

2. Research Methodology
2.1 Data Source
2.1.1 Primary Sources
2.1.2 Secondary Sources

2.2 Research Approach
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach

2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Global Heart Pump Device Market
5.1 Historical Market Trends
5.2 Market Forecast

6. Heart Pump Device Market Share Analysis
6.1 By Product
6.2 By Type
6.3 By End Use
6.4 By Countries

7. Product - Historical and Current Market Trends & Forecast
7.1 Ventricular Assist Devices (VADs)
7.2 Intra-aortic balloon pumps (IABPs)
7.3 Extracorporeal Membrane Oxygenation (EMCO)
7.4 Total Artificial Hearts (TAHs)

8. Type - Historical and Current Market Trends & Forecast
8.1 Implanted Heart Pump Device
8.2 Extracorporeal Heart Pump Device

9. End Use - Historical and Current Market Trends & Forecast
9.1 Hospitals
9.2 Cardiac Centers
9.3 Research Institutes

10. Countries - Historical and Current Market Trends & Forecast
10.1 North America
10.1.1 United States
10.1.2 Canada

10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa
10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa

11. Porter’s Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes

12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat

13. Merger and Acquisition

14. Key Players Analysis
14.1 Abbott Inc.
14.1.1 Overviews
14.1.2 Key Person
14.1.3 Recent Developments
14.1.4 SWOT Analysis
14.1.5 Revenue Analysis

14.2 Getinge AB.
14.2.1 Overviews
14.2.2 Key Person
14.2.3 Recent Developments
14.2.4 SWOT Analysis
14.2.5 Revenue Analysis

14.3 Teleflex Incorporated
14.3.1 Overviews
14.3.2 Key Person
14.3.3 Recent Developments
14.3.4 SWOT Analysis
14.3.5 Revenue Analysis

14.4 Fresenius SE & Co. KGaA
14.4.1 Overviews
14.4.2 Key Person
14.4.3 Recent Developments
14.4.4 SWOT Analysis
14.4.5 Revenue Analysis

14.5 LivaNova PLC
14.5.1 Overviews
14.5.2 Key Person
14.5.3 Recent Developments
14.5.4 SWOT Analysis
14.5.5 Revenue Analysis

14.6 CorWave SA
14.6.1 Overviews
14.6.2 Key Person
14.6.3 Recent Developments
14.6.4 SWOT Analysis
14.6.5 Revenue Analysis

14.7 JARVIK HEART, INC.
14.7.1 Overviews
14.7.2 Key Person
14.7.3 Recent Developments
14.7.4 SWOT Analysis
14.7.5 Revenue Analysis

14.8 ABIOMED
14.8.1 Overviews
14.8.2 Key Person
14.8.3 Recent Developments
14.8.4 SWOT Analysis
14.8.5 Revenue Analysis